Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
14 Jan 2026 Job Information Organisation/Company IMT MINES ALES Research Field Engineering » Electronic engineering Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage
-
IMT mines Alès, Mines Saint Etienne (50%/50%) | Ales, Languedoc Roussillon | France | about 2 months ago
9 Jan 2026 Job Information Organisation/Company IMT mines Alès, Mines Saint Etienne (50%/50%) Research Field Medical sciences Computer science » Database management Engineering Researcher Profile
-
the interface of machine learning and biology (tools developed by the team: https://github.com/cantinilab ). The team is composed of 8 people : 3PhD students, 3 post doc, 1 research engineer and 1 assistant
-
Skills :Programming, Research Knowledge :IA, Deep Learning, Python Where to apply Website https://rubis.univ-spn.fr/offres/voir/206 Requirements Specific Requirements Be a graduate of an Engineering
-
(MESR). The Marie Sklodowska-Curie GLYCOCALYX doctoral network (https://www.glycocalyx.org/ ) brings together 15 European partners implementing a multidisciplinary research and training program to study
-
20 Feb 2026 Job Information Organisation/Company Université Grenoble Alpes Research Field Technology Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage Researcher (R1
-
28 Feb 2026 Job Information Organisation/Company Mines Paris Research Field Technology Physics Medical sciences Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage
-
Ecole des Mines de Saint-Étienne | Gardanne, Provence Alpes Cote d Azur | France | about 2 months ago
new therapeutic avenues for tissue engineering, regenerative medicine and inflammation disorders. This inflammation on a chip device is expected to become an essential model for studying immune cells in
-
industriels (hydrocarbures, combustion), ainsi qu'en biomédecine, où cette longueur d'onde présente une absorption efficace par les tissus biologiques. Les développements récents montrent également leur intérêt
-
engineer (IR) for a 12-month period, aims to develop a new generation of anticancer drugs called degraders (PROteolysis TArgeting Chimeras, PROTACs). These innovative molecules do not simply block a target